{
    "clinical_study": {
        "@rank": "48691", 
        "arm_group": [
            {
                "arm_group_label": "EVARREST\u2122 Fibrin Sealant Patch", 
                "arm_group_type": "Experimental", 
                "description": "EVARREST\u2122 Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts\u2014 a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin)."
            }, 
            {
                "arm_group_label": "Topical hemostat", 
                "arm_group_type": "Active Comparator", 
                "description": "Equine collagen with Human Fibrinogen and Human Thrombin"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to evaluate the safety and effectiveness of the EVARREST\u2122\n      Fibrin Sealant Patch as an adjunct to hemostasis during cardiovascular surgery."
        }, 
        "brief_title": "The Fibrin Pad CV Phase III Study", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Cardiovascular Disease", 
        "condition_browse": {
            "mesh_term": "Cardiovascular Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects \u226518 years of age, requiring an elective or urgent, open aortic surgical\n             procedure utilizing cardiopulmonary bypass.  Subjects in Japan between \u226518 and <20\n             years of age will require consent by the subject's legal representative\n\n          -  Subjects must be willing to participate in the study and provide written informed\n             consent.\n\n          -  Presence of an appropriate Target Bleeding Site (TBS) along the anastomotic suture\n             line, involving a synthetic aortic graft, as identified intra-operatively by the\n             investigator;\n\n        Exclusion Criteria:\n\n          -  Subjects with known intolerance to blood products or to one of the components of the\n             study product or unwilling to receive blood products;\n\n          -  Exposure to another investigational drug or device in a clinical trial within 30 days\n             prior to surgery or anticipated in the 60 day follow up period after surgery.\n\n          -  Female subjects who are pregnant or nursing.\n\n          -  TBS is from a large defects in visible arteries or veins where the injured vascular\n             wall requires repair and maintenance of vessel patency or where there would be\n             persistent exposure of EVARREST\u2122 Fibrin Sealant Patch to blood flow and/or pressure\n             during absorption of the product;\n\n          -  TBS with major arterial bleeding requiring suture or mechanical ligation;\n\n          -  TBS involves an expanded polytetrafluoroethylene (ePTFE) graft\n\n          -  TBS within an actively infected field;\n\n          -  Bleeding site is in, around, or in proximity to foramina in bone, or areas of bony\n             confine;\n\n          -  Subjects with any intra-operative findings identified by the investigator that may\n             preclude conduct of the study procedure;"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02040428", 
            "org_study_id": "BIOS-13-004", 
            "secondary_id": "2013-003464-31"
        }, 
        "intervention": [
            {
                "arm_group_label": "EVARREST\u2122 Fibrin Sealant Patch", 
                "intervention_name": "EVARREST\u2122 Fibrin Sealant Patch", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Topical hemostat", 
                "intervention_name": "Topical hemostat", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Fibrin Tissue Adhesive"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Cardiovascular Diseases", 
            "Fibrin Sealant", 
            "Hemostatics", 
            "Coagulants"
        ], 
        "lastchanged_date": "February 25, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46290"
                    }, 
                    "name": "Clinical Investigation Site #14"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Orleans", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70121"
                    }, 
                    "name": "Clinical Investigation Site #19"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21201"
                    }, 
                    "name": "Clinical Investigation Site #16"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bethesda", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20814"
                    }, 
                    "name": "Clinical Investigation Site #21"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Clinical Investigation Site #17"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paterson", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07503"
                    }, 
                    "name": "Clinical Investigation Site #10"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "Clinical Investigation Site #12"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19102"
                    }, 
                    "name": "Clinical Investigation Site #20"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Clinical Investigation Site #18"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Camperdown", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2050"
                    }, 
                    "name": "Clinical Investigation Site #72"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sydney", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2010"
                    }, 
                    "name": "Clinical Investigation Site #73"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brisbane", 
                        "country": "Australia", 
                        "state": "Queensland", 
                        "zip": "4000"
                    }, 
                    "name": "Clinical Investigation Site #71"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bedford Park", 
                        "country": "Australia", 
                        "state": "South Australia", 
                        "zip": "5042"
                    }, 
                    "name": "Clinical Investigation Site #74"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3050"
                    }, 
                    "name": "Clinical Investigation Site #70"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gent", 
                        "country": "Belgium", 
                        "zip": "9000"
                    }, 
                    "name": "Clinical Investigation Site #40"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bristol", 
                        "country": "United Kingdom", 
                        "state": "England", 
                        "zip": "BS2 8HW"
                    }, 
                    "name": "Clinical Investigation Site #33"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cottingham", 
                        "country": "United Kingdom", 
                        "state": "England", 
                        "zip": "HU16 5JQ"
                    }, 
                    "name": "Clinical Investigation Site #35"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom", 
                        "state": "England", 
                        "zip": "M13 9WL"
                    }, 
                    "name": "Clinical Investigation Site #34"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aberdeen", 
                        "country": "United Kingdom", 
                        "state": "Scotland", 
                        "zip": "AB25 2ZN"
                    }, 
                    "name": "Clinical Investigation Site #32"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clydebank", 
                        "country": "United Kingdom", 
                        "state": "Scotland", 
                        "zip": "G81 4DY"
                    }, 
                    "name": "Clinical Investigation Site #31"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edinburgh", 
                        "country": "United Kingdom", 
                        "state": "Scotland", 
                        "zip": "EH16 4SA"
                    }, 
                    "name": "Clinical Investigation Site #30"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Belgium", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single-blinded, Randomized, Controlled, Comparative Phase III Study Evaluating the Safety and Effectiveness of EVARREST\u2122 Fibrin Sealant Patch as an Adjunct to Hemostasis During Cardiovascular Surgery", 
        "overall_contact": {
            "email": "jbatill2@its.jnj.com", 
            "last_name": "Jonathan Batiller, MBA", 
            "phone": "908-218-2492"
        }, 
        "overall_official": {
            "affiliation": "Ethicon, Inc.", 
            "last_name": "Jerome Riebman, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Japan: Pharmaceuticals and Medical Devices Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Hemostasis at the TBS at 3-minutes following treatment application and with no re-bleeding requiring treatment at the TBS any time prior to initiation of final chest wall closure. Hemostasis is defined as no detectable bleeding at the TBS.", 
            "measure": "Hemostasis at the Target Bleeding Site (TBS) at 3-minutes following treatment application", 
            "safety_issue": "Yes", 
            "time_frame": "Intraoperative"
        }, 
        "removed_countries": {
            "country": "Japan"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02040428"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Hemostasis at the TBS at 6-minutes following treatment application and with no re-bleeding requiring treatment at the TBS any time prior to initiation of final chest wall closure.", 
                "measure": "Hemostasis at the Target Bleeding Site (TBS) at 6-minutes following treatment application", 
                "safety_issue": "Yes", 
                "time_frame": "Intraoperative"
            }, 
            {
                "description": "Hemostasis at the TBS at 10-minutes following treatment application and with no re-bleeding requiring treatment at the TBS any time prior to initiation of final chest wall closure.", 
                "measure": "Hemostasis at the Target Bleeding Site (TBS) at 10-minutes following treatment application", 
                "safety_issue": "Yes", 
                "time_frame": "Intraoperative"
            }, 
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Through 60-day follow-up"
            }
        ], 
        "source": "Ethicon, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ethicon, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}